Senate Launches Investigation of Abortion Pill Manufacturers

The Senate has launched an investigation into the companies that make the deadly and dangerous abortion pill – which has killed millions of babies and injured thousands of women.

U.S. Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy, R-La., joined by Sens. Steve Daines, R-Mont., Lindsey Graham, R-S.C., Cindy Hyde-Smith, R-Miss., and James Lankford, R-Okla., has launched an investigation into three manufacturers of the chemical abortion drug mifepristone, raising serious concerns about compliance with federal safety protocols and the unchecked spread of mail-order abortions that flout state laws protecting unborn children.

The senators sent letters to Danco Laboratories, GenBioPro and Evita Solutions requesting information on their vendors, audits of certified prescribers and explanations for directing patients to online sellers that appear to bypass the Food and Drug Administration’s Risk Evaluation and Mitigation Strategy requirements for the high-risk drug.

The inquiries also seek details on why prescriptions are issued beyond the FDA-approved 10-week limit, when the drugs are not approved and risks of failure and complications rise sharply that could kill or injure women as well as the baby.

Click Like if you are pro-life to like the LifeNews Facebook page!

In a separate letter to the FDA, the lawmakers urged the agency to investigate potential REMS violations and take immediate enforcement action to uphold basic health and safety standards for women.

The oversight comes as a new report from the pro-abortion Guttmacher Institute estimates more than 1.1 million abortions in the United States in 2025, including notable growth in mail-order chemical abortions even in states that have enacted laws to protect babies throughout pregnancy.

Susan B. Anthony Pro-Life America President Marjorie Dannenfelser said the numbers show that abortion is not declining after the Dobbs decision but is instead being driven by mail-order drugs that ignore state protections.

“Abortion numbers are up, not down after Dobbs, driven by mail-order drugs flooding the states without regard for their laws. We are now at over 1.1 million abortions per year,” Dannenfelser said. “Chairman Cassidy and fellow pro-life senators are boldly confronting this crisis head-on, demanding real accountability and safety for women and girls.”

She added that the companies are capitalizing on relaxed Biden-era policies that allowed potent abortion drugs — carrying a black box warning — to be sold online with a credit card and shipped by mail without any in-person medical evaluation.

“Companies whose sole source of revenue is abortion drugs – which carry a black box warning – are raking in millions while their inherently risky, abuse-prone drug sends thousands of women to emergency rooms, enables abusers, systematically kills countless unborn children, and brazenly undermines democratically enacted state protections,” Dannenfelser said. “Their disregard for even the few remaining safety standards, and the lack of transparency around these secretive entities, is deeply troubling.”

Dannenfelser emphasized that the Trump-Vance administration has both the authority and responsibility to act.

“The Trump-Vance FDA has both the authority and the duty to act immediately, which voters across the board strongly support and which the GOP base demands,” she said.

National Right to Life voiced strong support for the Senate letters, which examine whether manufacturers and distributors are following federal rules for mifepristone and address the failure to curb illegal online abortion pill sales.

“These letters raise serious and long-overdue questions about whether federal protocols are being followed—and whether women are being put at risk as a result,” National Right to Life President Carol Tobias said. “The American people deserve transparency, accountability, and above all, protection from dangerous and unlawful practices.”

The letters highlight potential shortcomings in ensuring REMS compliance, including proper certification of prescribers, informed consent on risks and availability of emergency care.

NARLC said online distribution often involves minimal screening, raising questions about accurate determination of gestational age, diagnosis of ectopic pregnancies and access to follow-up medical care. They also document the proliferation of unapproved and misbranded chemical abortion drugs sold online in violation of federal law, frequently originating overseas without proper labeling or oversight.

“Federal law is clear: unapproved and misbranded drugs cannot be sold in the United States,” Tobias said. “Yet these illegal online operations continue to flourish, often encouraging women to conceal critical medical information if complications arise. That is a direct threat to patient safety.”

Tobias noted that recent policy changes — such as eliminating in-person dispensing requirements and reducing reporting of non-fatal adverse events — have weakened safeguards and made it harder to fully understand the drug’s risks.

“Women deserve real medical care, not drugs dispensed through anonymous websites with little to no oversight,” she said. “We commend the Senate HELP Committee for taking these concerns seriously and look forward to meaningful action that prioritizes women’s health and safety.”

Recent surveys underscore public support for stronger protections.

A Cygnal poll found Republican primary voters overwhelmingly oppose mail-order abortion drugs, while a McLaughlin & Associates survey showed 7 in 10 likely voters — including 57% of liberals — favor requiring an in-person doctor visit before prescribing the drugs.

The post Senate Launches Investigation of Abortion Pill Manufacturers appeared first on LifeNews.com.